5 results about "Osseous metastasis" patented technology

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide.

The invention relates to the technical field of focused ultrasound, in particular to a focused ultrasound path optimization method and system for a tumor bone metastasis focus. The method comprises the following steps: firstly, acquiring each candidate sound beam path of a transducer array and a unit path comprising each transducer; further obtaining an energy consumption coefficient according to the spatial distribution and acoustic resistance of voxels on the target path; further obtaining a damage coefficient according to the normal vector deviation corresponding to each skeleton interface voxel on the target path in combination with the spatial distribution of the skeleton interface voxels; further obtaining the path optimization degree according to the overall distribution of the energy consumption coefficient and the damage coefficient; and finally, selecting an optimal sound beam path based on the path optimization degree. According to the method, the energy consumption of each candidate sound beam path and the bone interface injury risk are quantified, the path optimization degree is comprehensively evaluated, automatic optimization of safe and efficient paths in bone metastasis focus focused ultrasound treatment is achieved, and the problem that in the prior art, a multi-path comprehensive optimization mechanism is lacked is solved.

The invention belongs to the field of biological medicine, and particularly relates to a preparation for targeted therapy of prostatic cancer osseous metastasis. The formulations provided herein include at least one of a nucleic acid encoding a protein, a vector, a cell, and a lipid nanoparticle RNA complex. The preparation can effectively inhibit the progress of the prostate cancer osseous metastasis, and provides a new direction for the treatment of the prostate cancer osseous metastasis.

The invention discloses a system for identifying multiple myeloma and bone metastatic tumor based on 18F-FDG PET / CT parameters. The system comprises a data acquisition module, a scoring model calculation module and an evaluation module. The data acquisition module is used for acquiring 18F-FDG PET / CT parameters of a patient as characteristic values, the scoring model is used for calculating a judgment score of the characteristic values by adopting a linear regression model, and the evaluation module is used for acquiring an identification result by adopting a threshold value method according to the judgment score and outputting the identification result to a user. By adopting the system, whether the patient is the multiple myeloma can be quickly evaluated, medical staff can be helped to identify and judge different disease patients with similar symptoms, and high-risk patients with the multiple myeloma or patients with the multiple myeloma can be quickly identified.